The timing of the launch was in line with expectations, said the broker, with the service to be offered to large employer groups and channel partners such as GP networks.
Dialogue with these has been underway since the announcement of the service on 11 May, added the broker.
Finncap left its forecasts unchanged but added there is room for upside depending on uptake of the test.
Earlier, Open Orphan had said samples will be tested in the company’s London lab with results returned within 48 hours.
Subsidiary hVIVO is using the Quotient MosaiQ system and MosaiQ COVID-19 Antibody Microarray, which it said has the “best-in-class COVID-19 antibody testing performance”.
In a statement, Open Orphan chairman Cathal Friel said: “We are very excited to be offering this service and I am confident our work will help large companies and clinics in the UK test their staff and patients to ensure the safety of all employees.”